Stocks Health care SNTI
NASDAQ · Health careSenti Biosciences Holdings, Inc. (SNTI)
It posted a net loss of $49.6M. In fiscal 2025 capital spending exceeded operating cash flow by $43.6M. At June 30, 2026 it held $6.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Senti Biosciences Holdings, Inc.
- Net worth
- Senti Biosciences Holdings, Inc. has a market value (market cap) of $4.9M at the latest share price, and shareholders' equity of -$3.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $22K, with a net loss of $61.4M.
- Cash flow
- In fiscal 2025 operations used $43.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Senti Biosciences Holdings, Inc. does
Senti Biosciences Holdings, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SNTI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $22K | -$61.4M | -$2.73 | -$43.6M |
| 2024 | $0 | -$52.8M | -$12.03 | -$41.4M |
| 2023 | $2.6M | -$71.1M | -$16.01 | -$64.4M |
| 2022 | $4.3M | -$58.2M | -$22.31 | -$76.3M |
| 2021 | $2.8M | -$55.3M | -$190.12 | -$40.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SNTI ranks in Health care
Latest SEC filings
What Senti Biosciences Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026Merger proxy statement DEFM14A
- September 24, 2026Executive or director change8-KBrenda Cooperstone has resigned from the Board of Directors of Senti Biosciences.
- September 24, 2026Form PRER14A filing PRER14A
- September 22, 2026
- September 11, 2026Activist stake changed SCHEDULE 13D/A
- September 10, 2026
- September 4, 2026Form PRER14A filing PRER14A
- September 4, 2026Additional proxy material DEFA14A
- September 4, 2026
- September 2, 2026Additional proxy material DEFA14A
Insider trades
What the people running Senti Biosciences Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 9, 2026 | Lu Timothy KCEO, Director | Shares withheld for tax | 80,666 | - |
| March 9, 2026 | Rajangam KanyaPres. & Chief Med. & Dev. Off. | Shares withheld for tax | 10,757 | - |
| February 2, 2026 | Lu Timothy KCEO, Director | Shares withheld for tax | 4,191 | - |
| February 2, 2026 | Rajangam KanyaPres. & Chief Med. & Dev. Off. | Shares withheld for tax | 1,384 | - |
Who owns SNTI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Celadon Partners SPV 2413D, may seek influence with 2 related filers | 54.6% | September 11, 2026 |
| Bayer HealthCare LLC13D, may seek influence with 3 related filers | 17.82% | April 16, 2026 |
| New Enterprise Associates 15, L.P.13D, may seek influence with 6 related filers | 12.1% | March 31, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 8.12% | May 15, 2025 |
Largest institutional holders
Insiders
2 insiders reported holding 714,426 shares in total, about $112.3K at the last price.
| Holder | Shares |
|---|---|
| Lu Timothy KCEO, Director | 639,583 |
| Rajangam KanyaPres. & Chief Med. & Dev. Off. | 74,843 |
Questions about SNTI
What does Senti Biosciences Holdings, Inc. do?
Senti Biosciences Holdings, Inc. is a company in the Health care sector, listed on NASDAQ as SNTI. Its shares trade on NASDAQ under the ticker SNTI.
What is Senti Biosciences Holdings, Inc.'s net worth?
Senti Biosciences Holdings, Inc. has a market value (market cap) of $4.9M at the latest share price, and shareholders' equity of -$3.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Senti Biosciences Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $49.6M.
When did Senti Biosciences Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the merger proxy statement from September 24, 2026.
Similar companies
Compare SNTI with
Follow SNTI
Get an email when Senti Biosciences Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Senti Biosciences Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.